Ryo Okazaki
Overview
Explore the profile of Ryo Okazaki including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
74
Citations
1002
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Baba S, Kawasaki T, Hirano S, Nakamura T, Asano T, Okazaki R, et al.
EClinicalMedicine
. 2025 Jan;
78():102936.
PMID: 39764541
Background: Pancreatic cancer is highly aggressive and has a low survival rate primarily due to late-stage diagnosis and the lack of effective early detection methods. We introduce here a novel,...
2.
Hotta Y, Yagoshi C, Okazaki R, Ikeda M
J Pestic Sci
. 2022 Jul;
47(2):69-77.
PMID: 35800391
The purpose of this study was to demonstrate the inhibitory effect of chemicals on methane emissions in paddy soil. We found that (4-hydroxyphenyl) chloromethanesulfonate (C-1) has a methanogenic inhibition activity,...
3.
Okazaki R, Poudel S, Hane Y, Saito T, Muto J, Syoji Y, et al.
Asian J Endosc Surg
. 2021 Nov;
15(2):328-334.
PMID: 34749433
Introduction: The laparoscopic approach for elective femoral herniorrhaphy is well established. However, femoral hernias often present as incarcerations and require emergency repair surgery, mainly using the open approach. This study...
4.
Ito N, Kubota T, Kitanaka S, Fujiwara I, Adachi M, Takeuchi Y, et al.
J Bone Miner Metab
. 2021 Jul;
39(6):1066-1075.
PMID: 34255195
Introduction: Measurement of fibroblast growth factor 23 (FGF23) has been reported to be clinically useful for the differential diagnosis of chronic hypophosphatemia. However, assays for research use only are available...
5.
Okazaki R
Clin Calcium
. 2018 Jun;
28(7):947-956.
PMID: 29950548
Obesity is associated with lower serum 25(OH)D level via several mechanisms including sequestration of fat soluble vitamin D in increased fat mass. Since obesity is the major cause of insulin...
6.
Okazaki R, Muraoka R, Maehara M, Inoue D
J Bone Miner Metab
. 2018 May;
37(1):185-197.
PMID: 29737412
Factors associated with an inadequate response (IR) to bisphosphonates have been reported in many countries, but not in Japan, where the approved dose is half the global dose. We analyzed...
7.
Hagino H, Soen S, Sugimoto T, Endo N, Okazaki R, Tanaka K, et al.
J Bone Miner Metab
. 2018 Mar;
37(2):273-281.
PMID: 29523963
We investigated changes in quality of life (QOL), including pain, in Japanese women aged ≥ 55 years who were diagnosed as having osteoporosis at 265 centers across Japan and treated...
8.
Okazaki R
Clin Calcium
. 2017 Oct;
27(11):1601-1608.
PMID: 29074833
Serum 25(OH)D level reflects bodily vitamin D store. Recently published "Assessment criteria for vitamin D deficiency/insufficiency in Japan" defines vitamin D sufficiency as 25(OH)D level of 30 ng/mL or more,...
9.
Okazaki R
Clin Calcium
. 2017 Jan;
27(2):263-271.
PMID: 28123129
Bisphosphonates have been explored possible combination and/or sequential use with other anti-osteoporotic medications including PTH. Besides with vitamin D(metabolites), combination treatment had been uncommon mainly because there had not been...
10.
Okazaki R, Ozono K, Fukumoto S, Inoue D, Yamauchi M, Minagawa M, et al.
Endocr J
. 2016 Dec;
64(1):1-6.
PMID: 28003569
Vitamin D is indispensable for the maintenance of bone and mineral health. Inadequate vitamin D action increases the risk for various musculoskeletal/mineral events including fracture, fall, secondary hyperparathyroidism, diminished response...